RT Journal Article
SR Electronic
T1 Does the Pareto Principle describe parasite counts in humans? The case of hookworm in pregnant women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.30.20249036
DO 10.1101/2020.12.30.20249036
A1 Yenifer Orobio
A1 Neal Alexander
YR 2021
UL http://medrxiv.org/content/early/2021/01/04/2020.12.30.20249036.abstract
AB The Pareto Principle (PP) — that 80% of an attribute are found in 20% of individuals — is one way to characterize heterogeneity in infectious diseases. An alternative is the dispersion parameter (k) of the negative binomial distribution (NBD). The NBD has two parameters, while the PP is a single property which may hold for any distribution family. The objectives of the current work are: a) to obtain a relation between the PP and NBD, i.e. to specify which combinations of NBD parameters comply with the PP; b) for hookworm, a soil-transmitted intestinal parasite of humans, to identify whether the PP or the NBD is a more parsimonious description of heterogeneity of infection load. For objective a), an empirical relation is found in the form of a saw-toothed line on a plot of k against the mean, reaching an asymptote of approximately 0.24. For objective b), we estimate k and the mean from nine studies from a systematic review of hookworm in pregnant women. Seven studies had higher heterogeneity than the PP, ranging from 83:20 to 100:20: we call these super-Pareto. One study was sub-Pareto (74:20), and one was Pareto (80:20). This suggests that at least two parameters, as supplied by the NBD, are necessary to describe the heterogeneity of hookworm. The probability of reaching a target reduction in prevalence is less when there is greater aggregation, which suggests that estimating aggregation via a subsample could be worthwhile, in order to set a target coverage threshold before starting mass drug administration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNA receives salary support from grant number 1U19AI129910-01 from the National Institutes of Health of the United States of America (www.nih.gov) awarded to Dr Nancy Gore Saravia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the Human Ethics Committee of the Faculty of Health of Universidad del Valle (approval number 083-015).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript and its supporting information.